Skip to main content Skip to search Skip to main navigation

Swissmedic: Invalid Certification of the Notified Body ECM

On 9 January 2024, the Swiss Medicines Agency Swissmedic informed about critical deficits in the system of medical device regulation. 

To ensure safety and efficiency, medical devices and the quality management system of medical device manufacturers are inspected and continuously monitored by notified bodies. The German notified body ECM (ECM-Zertifizierungsgesellschaft für Medizinprodukte in

Europa GmbH, Aachen) used to be such a notified body until its designation expired on 25 May 2020 and has not been renewed by the corresponding German authority. Since then, ECM-certified products have no longer been monitored in accordance with the requirements of the Therapeutic Products Act.

Last year, Swissmedic discovered that ECM certified medical devices of foreign manufacturers were still being sold in Switzerland. In response, the Swiss authority informed the approximately 980 registered Swiss authorised representatives of foreign manufacturers about the problem in June 2023 and asked them to review their mandates.

During the period from July to October 2023, the Swiss authority then carried out extensive research for a sample check. This revealed that 7 of the 15 specifically selected authorised representatives had products with an ECM certificate in their portfolio.

Swissmedic has ordered the authorised representatives concerned to take corrective action to ensure that the products distributed in Switzerland comply with the regulatory requirements.


Source:

Swissmedic:  Announcements on market control issues

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
What are the Prospects and Developments in the Operation of Computerised Systems?

What are the Prospects and Developments in the Operation of Computerised Systems?

Here's the answer:
Read more
Previous
Next